[go: up one dir, main page]

IS7223A - Meðhöndlun á alvarlegri lungnabólgu með inngjöf af vefjaþáttar taugabrautalata (TFPI) - Google Patents

Meðhöndlun á alvarlegri lungnabólgu með inngjöf af vefjaþáttar taugabrautalata (TFPI)

Info

Publication number
IS7223A
IS7223A IS7223A IS7223A IS7223A IS 7223 A IS7223 A IS 7223A IS 7223 A IS7223 A IS 7223A IS 7223 A IS7223 A IS 7223A IS 7223 A IS7223 A IS 7223A
Authority
IS
Iceland
Prior art keywords
tfpi
treatment
severe pneumonia
pneumonia
severe
Prior art date
Application number
IS7223A
Other languages
English (en)
Inventor
A. Creasey Abla
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of IS7223A publication Critical patent/IS7223A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS7223A 2001-10-15 2004-04-15 Meðhöndlun á alvarlegri lungnabólgu með inngjöf af vefjaþáttar taugabrautalata (TFPI) IS7223A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032624 WO2003032904A2 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
IS7223A true IS7223A (is) 2004-04-15

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7224A IS7224A (is) 2001-10-15 2004-04-15 Meðhöndlun á graftarsótt með smáskammta inngjöf af vefjaþáttar taugabrautalata (TFPI)
IS7223A IS7223A (is) 2001-10-15 2004-04-15 Meðhöndlun á alvarlegri lungnabólgu með inngjöf af vefjaþáttar taugabrautalata (TFPI)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7224A IS7224A (is) 2001-10-15 2004-04-15 Meðhöndlun á graftarsótt með smáskammta inngjöf af vefjaþáttar taugabrautalata (TFPI)

Country Status (17)

Country Link
US (2) US7674769B2 (is)
EP (2) EP1446140A4 (is)
JP (5) JP2005515214A (is)
KR (2) KR20040040489A (is)
CN (2) CN1604790A (is)
AU (2) AU2002340183B2 (is)
BR (2) BR0213293A (is)
CA (2) CA2463655A1 (is)
EA (2) EA200400548A1 (is)
HU (2) HUP0500472A2 (is)
IL (2) IL161408A0 (is)
IS (2) IS7224A (is)
MX (2) MXPA04003547A (is)
NO (2) NO20041997D0 (is)
PL (2) PL374506A1 (is)
WO (2) WO2003055442A2 (is)
ZA (2) ZA200403601B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374506A1 (en) * 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
ES2311789T3 (es) * 2003-01-08 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Composiciones liofilizadas estabilizadas que comprenden inhibidor de la via del factor tisular o variantes del inhibidor de la via del factor tisular.
CA2535562A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
WO2005110059A2 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
RU2007142192A (ru) * 2005-04-15 2009-05-20 Новартис Вэксинес Энд Дайэгностикс Инк. (Us) Лечение тяжелой внебольничной пневмонии с помощью введения ингибитора пути тканевого фактора (tfpi)
MX2007013876A (es) * 2005-05-06 2008-04-02 Novartis Ag Uso de inhibidor de la via del factor de tejido para tratar infecciones bacterianas severas.
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
ZA200800255B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
RU2008106460A (ru) * 2005-07-22 2009-08-27 Новартис АГ (CH) Антимикробный агент, взаимодействующий с системой комплемента
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
AU2012285875B2 (en) 2011-07-18 2016-11-10 Morphosys Ag Use of c-Fms antagonists
PT2781221T (pt) 2011-11-15 2020-06-01 Asahi Kasei Pharma Corp Medicamento para tratamento e/ou melhoria de sepsia
CN105121466A (zh) 2013-04-12 2015-12-02 莫佛塞斯公司 靶向m-csf的抗体
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2023142096A1 (en) * 2022-01-30 2023-08-03 Westlake University Composition and method for preventing and/or treating clostridioides difficile infections caused by clade 2 strains

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0179861A1 (en) 1984-04-19 1986-05-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
DE69118056T2 (de) 1990-08-27 1996-10-24 Monsanto Co Anticoagulatorische Zusammensetzung aus LACI und sulfatierten Polysacchariden
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
ES2139658T3 (es) 1992-06-01 2000-02-16 Chiron Corp Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica.
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1993025230A1 (en) 1992-06-11 1993-12-23 G.D. Searle & Co. Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
DE69637012T2 (de) 1995-06-07 2009-01-08 G.D. Searle Llc (N.D.Ges.D. Staates Delaware) Waessrige Formulierung enthaltend TFPI und Lösungsvermittlers
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
KR100442758B1 (ko) 1996-03-25 2004-10-06 사이단호진 가가쿠오요비겟세이료호겐쿠쇼 조직인자응고계억제제함유혈관신생저해제
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
EP1005551A2 (en) * 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
JP2002530353A (ja) 1998-11-20 2002-09-17 イーライ・リリー・アンド・カンパニー ウイルス性出血熱の処置法
WO2000077254A1 (en) * 1999-06-11 2000-12-21 The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
JP2003530819A (ja) 1999-06-14 2003-10-21 ノボ ノルディスク アクティーゼルスカブ ＦＶＩＩａ／ＴＦ活性阻害化合物
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
JP2003519196A (ja) 2000-01-06 2003-06-17 イーライ・リリー・アンド・カンパニー 炎症性疾患および呼吸器疾患を処置するための併用療法
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
CN1404396A (zh) 2000-02-16 2003-03-19 西北大学 类多肽肺表面活性剂
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002102325A2 (en) 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
EP1383885A4 (en) 2001-04-04 2005-11-30 American Diagnostica Inc METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
KR20040040489A (ko) 2004-05-12
CA2463655A1 (en) 2003-04-24
IL161408A0 (en) 2004-09-27
HUP0501111A2 (en) 2007-12-28
KR20050036867A (ko) 2005-04-20
WO2003032904A3 (en) 2004-03-04
EA200400548A1 (ru) 2005-06-30
EP1446140A4 (en) 2007-03-07
AU2002365131B2 (en) 2007-03-01
ZA200403601B (en) 2006-06-28
HUP0500472A2 (hu) 2005-08-29
US7674769B2 (en) 2010-03-09
US20030139339A1 (en) 2003-07-24
JP2010006839A (ja) 2010-01-14
IL161407A0 (en) 2004-09-27
PL374506A1 (en) 2005-10-31
JP2006008706A (ja) 2006-01-12
EP1446138A2 (en) 2004-08-18
AU2002340183B2 (en) 2008-11-13
ZA200403690B (en) 2005-03-08
JP2006008704A (ja) 2006-01-12
WO2003055442A3 (en) 2004-03-04
WO2003055442A2 (en) 2003-07-10
BR0213292A (pt) 2006-05-23
PL372138A1 (en) 2005-07-11
IS7224A (is) 2004-04-15
CN1604787A (zh) 2005-04-06
WO2003032904A2 (en) 2003-04-24
NO20041996D0 (no) 2004-05-14
US20030139340A1 (en) 2003-07-24
MXPA04003548A (es) 2004-07-22
BR0213293A (pt) 2004-12-21
MXPA04003547A (es) 2004-07-22
EP1446138A4 (en) 2007-03-14
EP1446140A2 (en) 2004-08-18
JP2005515214A (ja) 2005-05-26
AU2002365131A1 (en) 2003-07-15
CN1604790A (zh) 2005-04-06
JP2005506345A (ja) 2005-03-03
NO20041997D0 (no) 2004-05-14
CA2463738A1 (en) 2003-07-10
EA200400549A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
IS7223A (is) Meðhöndlun á alvarlegri lungnabólgu með inngjöf af vefjaþáttar taugabrautalata (TFPI)
DK1438306T3 (da) Derivater af UK-2A
DK1421841T3 (da) Mejetærsker
DE60220053D1 (de) Schaltkreis
DE60218932D1 (de) Integrierte Schaltkreisstruktur
IS6954A (is) Notkun á enantíómerískt hreinu essítalóprami
DE60207512D1 (de) Flexible Schaltung
DE60204155D1 (de) Filmmaterial
DE60226342D1 (de) Fluoriertes terpolymer
DE60218046D1 (de) Anlaufschaltung
DE60210848D1 (de) Verbinder
IS2523B (is) Turn vindorkuvers
PT1429926E (pt) Circuito de interligacao
NO20041968L (no) Anvendelse av cystationin
DE60203401D1 (de) Filmmaterial
DK1377544T3 (da) Oprensning af 2-nitro-4-methylsulfonylbenzoesyre
DE50200466D1 (de) Symmetrierübertrager
DE60221366D1 (de) Verbinder
DE60233695D1 (de) Verbinder
FI20011778A0 (fi) Ryhmälähetyksen toteutus
DE10249893B4 (de) Halbleiterschaltung
DE60200390D1 (de) Schaltwerk
ATA14062001A (de) Fassung
DK1373898T3 (da) Påvisning af inflammationer
DE60130812D1 (de) Okularlinse